150 Patients – 150 Times New Hope

Heidelberg, September 05, 2025 - We at PRECISIS are proud to announce a major milestone:

150 patients implanted with EASEE® across Europe.

This achievement marks a significant step forward in our mission to improve the lives of people living with drug-resistant focal epilepsy.

EASEE, which received its CE mark in September 2022, is now actively implanted by leading epileptologists and neurosurgeons in Germany, Austria, Switzerland, the UK, and Portugal. The low-invasive device is designed to reduce seizure frequency and enhance quality of life for patients when medication alone isn’t enough.

“This milestone is more than a number—it’s a reflection of the lives we’ve helped change,” says Karl Stoklosa, CEO of PRECISIS. “Every patient implanted with EASEE represents a story of hope, resilience, and progress. We are proud to work alongside dedicated clinicians across Europe who share our vision of transforming epilepsy care.”

Among the 150 patients are Ibrahim and Tim, two individuals who have publicly shared their journeys with EASEE. Ibrahim has been seizure-free for over three years, while Tim, who received EASEE in July 2024, has experienced a significant reduction in seizure frequency. Both describe the therapy as life-changing, giving them new energy, confidence, and a renewed sense of freedom.

Just a few months prior to this milestone, we published our 24-month clinical data, further validating the safety and efficacy of EASEE. The peer-reviewed study, published in Epilepsia, highlights sustained seizure reduction and improved patient outcomes over time. Read the study

Join the Movement

We continue to expand our network of clinical partners and are committed to making EASEE accessible to more patients across Europe and the United States.
To learn more about EASEE, follow us on LinkedIn and Instagram or contact us directly.